An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
NCT00002090
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
Concurrent Medication:
Allowed:
- Medications allowed under a Treatment IND program.
Patients must have:
- HIV infection.
- Disseminated Mycobacterium avium Complex.
- Fever (> 100 degrees F) that cannot be attributed to another active infection, and at least one other constitutional symptom (such as fatigue, malaise, anorexia).
- Life expectancy of at least the duration of the study.
- Consent of parent or guardian if below the legal age of consent.
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Known hypersensitivity or significant intolerance to macrolide antibiotics.
- Inability to take oral medications or a current condition likely to interfere with
drug absorption (e.g., gastrectomy).
Prior Medication:
Excluded:
- Treatment with an immunostimulant or immunomodulator compound such as
alpha-interferon, gamma-interferon, or any interleukin within 7 days prior to study
entry.
- Any other antibiotic with known activity against M. avium within 7 days prior to study
entry.
Not expected to comply with the requirements of the protocol, in the opinion of the
investigator.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- San Diego, California
- Fort Bragg, North Carolina
- Lackland Air Force Base, Texas
- Berkeley, California
- Mill Valley, California
- Oakland, California
- Orange, California
- San Francisco, California
- San Jose, California
- Groton, Connecticut
- Washington, District of Columbia
- Washington, District of Columbia
- Miami, Florida
- St Petersburg, Florida
- Tampa, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Chicago, Illinois
- New Orleans, Louisiana
- Kansas City, Missouri
- Durham, North Carolina
- Austin, Texas
- Austin, Texas
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- Hampton, Virginia
- Groton, Connecticut
- Boston, Massachusetts
- Bronx, New York
- Syracuse, New York
- Columbus, Ohio
- Lackland Air Force Base, Texas
- San Antonio, Texas
| Descriptive Information | |||
|---|---|---|---|
| Brief Title ICMJE | An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS) | ||
| Official Title ICMJE | An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS) | ||
| Brief Summary | To evaluate the efficacy and safety of two doses of azithromycin given chronically for the treatment of Mycobacterium avium bacteremia in AIDS patients. | ||
| Detailed Description | Not Provided | ||
| Study Type ICMJE | Interventional | ||
| Study Phase ICMJE | Not Applicable | ||
| Study Design ICMJE | Primary Purpose: Treatment | ||
| Condition ICMJE |
| ||
| Intervention ICMJE | Drug: Azithromycin | ||
| Study Arms ICMJE | Not Provided | ||
| Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||
| Recruitment Information | |||
| Recruitment Status ICMJE | Completed | ||
| Enrollment ICMJE | Not Provided | ||
| Original Enrollment ICMJE | Not Provided | ||
| Study Completion Date ICMJE | Not Provided | ||
| Primary Completion Date | Not Provided | ||
| Eligibility Criteria ICMJE | Inclusion Criteria Concurrent Medication: Allowed:
Patients must have:
Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded:
Prior Medication: Excluded:
Not expected to comply with the requirements of the protocol, in the opinion of the investigator. | ||
| Sex/Gender ICMJE |
| ||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||
| Accepts Healthy Volunteers ICMJE | No | ||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
| Listed Location Countries ICMJE | United States | ||
| Removed Location Countries | |||
| Administrative Information | |||
| NCT Number ICMJE | NCT00002090 | ||
| Other Study ID Numbers ICMJE | 058H 066-148 | ||
| Has Data Monitoring Committee | Not Provided | ||
| U.S. FDA-regulated Product | Not Provided | ||
| IPD Sharing Statement ICMJE | Not Provided | ||
| Responsible Party | Not Provided | ||
| Study Sponsor ICMJE | Pfizer | ||
| Collaborators ICMJE | Not Provided | ||
| Investigators ICMJE | Not Provided | ||
| PRS Account | NIH AIDS Clinical Trials Information Service | ||
| Verification Date | April 1996 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | |||